A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: University of Arizona, Tucson, Arizona +28 locations
Conditions: Type 2 Diabetes
Register for Updates
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462
Recruiting
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/22/2025
Locations: Research Site, La Jolla, California +74 locations
Conditions: Ophthalmic Safety in Patients With Breast Cancer
Register for Updates
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983
Recruiting
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital - Boston, Boston, Massachusetts +6 locations
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
The Use of CCK vs PS in Revision TKAs
NCT06782295
Recruiting
This study aims to compare the clinical impact of Constrained Condylar versus Posterior Stabilized Knee (PS) bearings on patient satisfaction and surgical outcomes including mid-term survivorship among patients undergoing revision total knee arthroplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Aseptic Loosening of Prosthetic Joint, Instability of Prosthetic Joint, Reimplantation for Periprosthetic Joint Infection, Femoral Revision Indicated, Tibial Component Revision
Register for Updates
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172
Recruiting
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. This study will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Precision NextGen Oncology and Research Center, Beverly Hills, California +7 locations
Conditions: Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, NSCLC, Pancreatic Adenocarcinoma, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Sun Valley Behavioral Med Center, Imperial, California +36 locations
Conditions: Schizophrenia
Register for Updates
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505
Recruiting
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: Rehabilitation & Neurological Services /ID# 270782, Huntsville, Alabama +40 locations
Conditions: Chronic Migraine
Register for Updates
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078
Recruiting
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness o... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Takeda Site 11, Redwood City, California +28 locations
Conditions: Idiopathic Hypersomnia
Register for Updates
ASCEND CSP IDE Study
NCT06830746
Recruiting
This is a prospective, multi-center, global, single-arm, pivotal investigational study designed to evaluate the safety and effectiveness of the CSP ICD Lead in a subject population indicated for ICD or CRT-D therapy. The clinical investigation will enroll up to 414 subjects at up to 70 participating centers from the United States, Canada, Europe, and Asia Pacific.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/22/2025
Locations: Arrhythmia Research Group, Jonesboro, Arkansas +12 locations
Conditions: Heart Failure, Ventricular Arrythmia
Register for Updates
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
NCT06840899
Recruiting
The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Supra-sacral Spinal Cord Injury, Spinal Cord Injury, Urinary Incontinence
Register for Updates
Bite Force Measurements
NCT06843525
Recruiting
ABSTRACT: Acute dental pain from untreated decay often drives patients to emergency rooms (ERs), where the lack of definitive dental treatment results in nearly 75% of these patients receiving analgesics, predominantly opioids. Addressing the need for non-opioid pain alternatives is crucial. Emerging evidence suggests that dental pain from pulpal and periodontal conditions (affecting the tooth's nerve and surrounding tissues) involves neuropathic mechanisms, such as mechanical allodynia (MA) and... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/22/2025
Locations: Rutgers School of Dental Medicine, Newark, New Jersey
Conditions: Irreversible Pulpitis, Apical Periodontitis, Pulpal Necrosis
Register for Updates
A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
NCT06846866
Recruiting
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/22/2025
Locations: Celerion, Tempe, Arizona
Conditions: Healthy Volunteers
Register for Updates